# Lucy Earl

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/lucy-earl/

## Facts

| Field | Value |
| --- | --- |
| Citations | 107 |
| Field | Coagulation, Bradykinin, Polyphosphates, and Angioedema |
| h-index | 7 |
| i10-index | 3 |
| Last Known Institution | Adelphi Group (United Kingdom) |
| OpenAlex ID | https://openalex.org/A5113112394 |
| Works | 18 |

## Researcher papers

- [Multi‐Tissue Epigenetic and Gene Expression Analysis Combined With Epigenome Modulation Identifies <i>RWDD2B</i> as a Target of Osteoarthritis Susceptibility](https://scholariq.org/papers/multi-tissue-epigenetic-and-gene-expression-analysis-combined-with-epigenome/)
- [Time from amyotrophic lateral sclerosis symptom onset to key disease milestones: analysis of data from a multinational cross-sectional survey](https://scholariq.org/papers/time-from-amyotrophic-lateral-sclerosis-symptom-onset-to-key-disease-milestones/)
- [Physician- and patient-reported outcomes by hereditary angioedema type: Data from a real-world study](https://scholariq.org/papers/physician-and-patient-reported-outcomes-by-hereditary-angioedema-type-data-from/)
- [Healthcare resource utilization at different stages of amyotrophic lateral sclerosis: Results from a real-world survey](https://scholariq.org/papers/healthcare-resource-utilization-at-different-stages-of-amyotrophic-lateral/)
- [Pegcetacoplan in paroxysmal nocturnal haemoglobinuria: Its use, its clinical effectiveness, and its influence on health‐related quality of life and productivity](https://scholariq.org/papers/pegcetacoplan-in-paroxysmal-nocturnal-haemoglobinuria-its-use-its-clinical/)
- [PB2056: PREVALENCE OF CLINICALLY SIGNIFICANT EXTRAVASCULAR HEMOLYSIS IN STABLE C5 INHIBITOR-TREATED PATIENTS WITH PNH AND ITS ASSOCIATION WITH DISEASE CONTROL, QUALITY OF LIFE AND TREATMENT SATISFACTION](https://scholariq.org/papers/pb2056-prevalence-of-clinically-significant-extravascular-hemolysis-in-stable-c5/)
- [Real-world outcomes in patients with hereditary angioedema prescribed lanadelumab versus other prophylaxis](https://scholariq.org/papers/real-world-outcomes-in-patients-with-hereditary-angioedema-prescribed/)
- [Comparison of Hereditary Angioedema Among Patients of Different Races and Ethnicities in the United States: Data From a Real-World Study](https://scholariq.org/papers/comparison-of-hereditary-angioedema-among-patients-of-different-races-and/)
- [Long-Term Real-World Outcomes in Patients with Hereditary Angioedema Receiving Lanadelumab for 3 or More Years](https://scholariq.org/papers/long-term-real-world-outcomes-in-patients-with-hereditary-angioedema-receiving/)
- [Real-World Treatment Outcomes of Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated with Pegcetacoplan and Complement Protein 5 Inhibitors (C5i)](https://scholariq.org/papers/real-world-treatment-outcomes-of-paroxysmal-nocturnal-hemoglobinuria-pnh/)

## Researcher topics

- [Coagulation, Bradykinin, Polyphosphates, and Angioedema](https://scholariq.org/topics/coagulation-bradykinin-polyphosphates-and-angioedema/)
- [Complement system in diseases](https://scholariq.org/topics/complement-system-in-diseases/)
- [Blood groups and transfusion](https://scholariq.org/topics/blood-groups-and-transfusion/)
- [Hemophilia Treatment and Research](https://scholariq.org/topics/hemophilia-treatment-and-research/)
- [Hemoglobinopathies and Related Disorders](https://scholariq.org/topics/hemoglobinopathies-and-related-disorders/)

## Researcher university

- [Adelphi Group (United Kingdom)](https://scholariq.org/institutions/adelphi-group-united-kingdom/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.